We compared different approaches using 129 leftover peripheral blood samples from CML patients with varying BCR::ABL1/ABL1 transcript levels, ranging from undetectable to 10%. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.